# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07012024_NRBO_Bautz.pdf
- Form4
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiomet...
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.
Data Will be Presented in Two Posters at the EASL Congress 2024